ABCL
AbCellera Biologics Inc.
$5.42
-3.56%
$1.6B
No data for this timeframe.
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders6 funds
Inst. Value$48.0M
Inst. Activity1 buys / 1 sells
Insider Activity3B / 0S
Insider Net $$371.8K
Reddit Sentiment75° Bullish
SEC Reports5
Recent Activity
Jun 5, 2026
SEC
AbCellera appointed Dr. Victor Sandor as an independent director on June 1, 2026. Dr. Sandor is a seasoned medical oncol
8-K — Impact 2/10
Jun 3, 2026
Insider
Booth Andrew sold 250,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Jun 3, 2026
Insider
Booth Andrew sold 250,000 shares
Chief Financial Officer @ $0.1900 ($47.5K)
May 18, 2026
short_volume
Short Volume: ABCL — 61.0% short (2.5M / 4.1M)
Short: 2,520,707 | Exempt: 0 | TRF Vol: 4,132,033 | Short Ratio: 61.0% | Off-exchange volume (dark p
May 14, 2026
Insider
Montalbano John S. bought 20,000 shares
Director @ $4.77 ($95.4K)
May 11, 2026
SEC
AbCellera reported Q1 2026 revenue of $8.3M (up 96% YoY from $4.2M) and a net loss of $43.2M ($-0.14/share), narrower th
8-K — Impact 7/10
Apr 21, 2026
SEC
Leerink Partners downgrades ABCL to Market Perform — PT $4 (-57%)
ANALYST-DOWNGRADE — Impact 1/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
2,389,229 shares ($8.2M)
Price Targets
$10.43
+96.8% upside
Strong Buy
Current $5.30
Low $7.00
Median $11.00
High $13.00
7 analysts
$7.00
$13.00
Analyst Ratings
3Strong Buy
10Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Apr 10, 2026 | Jones Trading | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.17 ▲ +15.0% | $-0.19 — $-0.16 | -42% YoY | 3 |
| Next Q | $-0.18 ▲ +13.8% | $-0.19 — $-0.17 | 7% YoY | 3 |
| Current FY | $-0.65 ▲ +7.6% | $-0.71 — $-0.59 | -33% YoY | 5 |
| Next FY | $-0.72 ▲ +8.1% | $-0.80 — $-0.56 | -10% YoY | 4 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP | $19.9M | ADD |
| MORGAN STANLEY | $10.3M | DOUBLED |
| BANK OF AMERICA CORP | $9.0M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $8.2M | TRIM |
| NORGES BANK | $603.2K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Booth Andrew | M | $0.00 |
| Jun 3, 2026 | Booth Andrew | M | $47.5K |
| May 14, 2026 | Montalbano John | BUY | $95.4K |
| Feb 27, 2026 | Thermopylae Holdings | BUY | $130.7K |
| Feb 27, 2026 | Booth Andrew | BUY | $145.7K |
Reddit Sentiment
75°
Bullish
Bearish
Neutral
Bullish
6 institutional holders with $48.0M total value (14,026,222 shares) as of 2025-Q4. Top holders: TWO, MORGAN, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | 5,810,985 | $19.9M | 41.4% | ADD +25.9% |
| 2 | MORGAN STANLEY | 3,001,850 | $10.3M | 21.4% | DOUBLED +180.1% |
| 3 | BANK OF AMERICA CORP /DE/ | 2,632,872 | $9.0M | 18.8% | DOUBLED +977.8% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 2,389,229 | $8.2M | 17.0% | TRIM -28.9% |
| 5 | NORGES BANK | 176,386 | $603.2K | 1.3% | NEW |
| 6 | WELLS FARGO & COMPANY/MN | 14,900 | $51.0K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 3,360,729 | 2,389,229 | -28.9% | $8.2M | 2025-Q4 |
| NORGES BANK | NEW | — | 176,386 | — | $603.2K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 4,110,852 | 5,175,142 | +25.9% | $26.0M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 996,927 | 2,792,142 | +180.1% | $14.0M | 2025-Q3 |
| UBS Group AG | TRIM | 3,447,925 | 2,489,200 | -27.8% | $12.5M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 224,365 | 2,418,304 | +977.8% | $12.2M | 2025-Q3 |
| NORGES BANK | EXIT | 630,938 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 3,126,789 | 4,110,852 | +31.5% | $14.1M | 2025-Q2 |
| UBS Group AG | TRIM | 5,082,183 | 3,447,925 | -32.2% | $11.8M | 2025-Q2 |
| NORGES BANK | NEW | — | 630,938 | — | $2.2M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 15,975 | 224,365 | +1304.5% | $769.6K | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,975,348 | 5,082,183 | +157.3% | $11.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 892,251 | 2,007,174 | +125.0% | $4.5M | 2025-Q1 |
| MORGAN STANLEY | ADD | 937,385 | 1,291,016 | +37.7% | $2.9M | 2025-Q1 |
| NORGES BANK | EXIT | 1,284,533 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 21,745 | 1,975,348 | +8984.1% | $5.8M | 2024-Q4 |
| NORGES BANK | ADD | 922,214 | 1,284,533 | +39.3% | $3.8M | 2024-Q4 |
| MORGAN STANLEY | ADD | 589,653 | 937,385 | +59.0% | $2.7M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 1,666,740 | 892,251 | -46.5% | $2.6M | 2024-Q4 |
3 unique insiders with 3 transactions. Net insider value: $371.8K ($371.8K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Booth Andrew | Chief Financial Officer | M | 250,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Booth Andrew | Chief Financial Officer | M | 250,000 | $0.1900 | $47.5K |
| May 14, 2026 | Montalbano John S. | Director | BUY | 20,000 | $4.77 | $95.4K |
| Feb 27, 2026 | Thermopylae Holdings Ltd. | 10%+ Owner | BUY | 38,000 | $3.44 | $130.7K |
| Feb 27, 2026 | Booth Andrew | Chief Financial Officer | BUY | 42,600 | $3.42 | $145.7K |
5 SEC filing reports analyzed. Sentiment: 3 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 4.6/10.
BEARISH
ANALYST-DOWNGRADE
1/10
Leerink Partners downgrades ABCL to Market Perform — PT $4 (-57%)
Apr 21, 2026
NEUTRAL
8-K
2/10
AbCellera appointed Dr. Victor Sandor as an independent director on June 1, 2026. Dr. Sandor is a se
Jun 5, 2026
BULLISH
8-K
7/10
AbCellera reported Q1 2026 revenue of $8.3M (up 96% YoY from $4.2M) and a net loss of $43.2M ($-0.14
May 11, 2026
BULLISH
CLUSTER
6/10
Two insiders at AbCellera Biologics purchased shares in the open market within the same week, includ
Mar 2, 2026
BULLISH
8-K
7/10
AbCellera reported strong financial results for 2025, with revenue nearly tripling to $75.1 million
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (87% buy). Based on 15 analysts: 3 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.43 mean target
+96.8% upside
Strong Buy (1.33)
$7.00 Low
$13.00 High
| Metric | Value |
|---|---|
| Current Price | $5.30 |
| Target Low | $7.00 |
| Target Mean | $10.43 |
| Target Median | $11.00 |
| Target High | $13.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.17 | $-0.19 | $-0.16 | -41.7% | +15.0% | 2↑ 0↓ | $0.0B | -54.1% | 3 |
| Next Q 2026-09-30 |
$-0.18 | $-0.19 | $-0.17 | 7.0% | +13.8% | 2↑ 0↓ | $0.0B | -14.2% | 3 |
| Current FY 2026-12-31 |
$-0.65 | $-0.71 | $-0.59 | -33.5% | +7.6% | 4↑ 0↓ | $0.0B | -57.4% | 5 |
| Next FY 2027-12-31 |
$-0.72 | $-0.80 | $-0.56 | -10.1% | +8.1% | 2↑ 0↓ | $0.0B | -3.4% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.170 | |
| 7d ago | $-0.198 | +0.027 |
| 30d ago | $-0.200 | +0.030 |
| 60d ago | $-0.200 | +0.030 |
| 90d ago | $-0.175 | +0.005 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Apr 10, 2026 | Jones Trading | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 10 | 2 | 0 | 0 | 87% | |
| May 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
75°
Bullish
Bearish
Neutral
Bullish
8 mentions
6 bullish
0 bearish
8 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
ABCL is the most slept-on biotech binary event of 2026 and you're all too busy buying 0DTE SPY puts to notice
▲ 1
💬 0
⚡ 0.5
Why is ABCL up so much today?
▲ 1
💬 1
⚡ 0.5
AbCellera and the novel hantavirus
▲ 1
💬 0
⚡ 0.5
May 18, 2026
short_volume
Short Volume: ABCL — 61.0% short (2.5M / 4.1M)
Short: 2,520,707 | Exempt: 0 | TRF Vol: 4,132,033 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_interest
FTD: ABCL — 108,660 shares ($0.6M) failed to deliver
Settlement: 20260512, Price: $5.25, FTD Value: $570,465, ABCELLERA BIOLOGICS INC. (CAN)
May 11, 2026
earnings_calendar
ABCL Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_volume
Short Volume: ABCL — 55.7% short (3.1M / 5.5M)
Short: 3,074,131 | Exempt: 14,048 | TRF Vol: 5,522,973 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 10, 2026
earnings_calendar
ABCL Q1 2026 Earnings Scheduled — 2026-05-10
May 8, 2026
short_volume
Short Volume: ABCL — 62.0% short (4.0M / 6.4M)
Short: 3,961,059 | Exempt: 20,258 | TRF Vol: 6,390,172 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: ABCL — 65.0% short (4.7M / 7.2M)
Short: 4,688,216 | Exempt: 8,784 | TRF Vol: 7,217,488 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: ABCL — 61.8% short (2.2M / 3.6M)
Short: 2,232,570 | Exempt: 205 | TRF Vol: 3,609,852 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_interest
FTD: ABCL — 376,377 shares ($1.8M) failed to deliver
Settlement: 20260506, Price: $4.66, FTD Value: $1,753,916.82, ABCELLERA BIOLOGICS INC. (CAN)
May 5, 2026
short_volume
Short Volume: ABCL — 64.6% short (3.4M / 5.2M)
Short: 3,391,606 | Exempt: 21,102 | TRF Vol: 5,246,430 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: ABCL — 66.2% short (2.7M / 4.0M)
Short: 2,655,174 | Exempt: 3,419 | TRF Vol: 4,009,640 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
short_interest
FTD: ABCL — 286,808 shares ($1.1M) failed to deliver
Settlement: 20260430, Price: $3.82, FTD Value: $1,095,606.56, ABCELLERA BIOLOGICS INC. (CAN)
Apr 29, 2026
short_interest
FTD: ABCL — 1,786,958 shares ($7.4M) failed to deliver
Settlement: 20260429, Price: $4.16, FTD Value: $7,433,745.28, ABCELLERA BIOLOGICS INC. (CAN)
Apr 28, 2026
short_interest
FTD: ABCL — 619,362 shares ($2.6M) failed to deliver
Settlement: 20260428, Price: $4.16, FTD Value: $2,576,545.92, ABCELLERA BIOLOGICS INC. (CAN)
Apr 27, 2026
short_volume
Short Volume: ABCL — 62.3% short (4.2M / 6.7M)
Short: 4,198,184 | Exempt: 25,612 | TRF Vol: 6,742,063 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)